Clinical trials: Chronic Schizophrenia
Hyperlipidemia, Diabetes
Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness
The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome.
- Conditions
- Hyperlipidemia, Diabetes, Hypertension
- Trial name
- NCT02029989
- Testing
- Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Schizophrenia, Medication Nonadherence
Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
The proposed, three phase project will refine and test a first-ever care approach in SSA that combines LAI with a behavioral program specifically intended to promote medication adherence in chronic psychotic disorders (CPDs).
- Conditions
- Schizophrenia, Medication Nonadherence, Schizo Affective Disorder
- Trial name
- CAPACITY (NCT04327843)
- Testing
- Customized Adherence Enhancement, Haloperidol Decanoate
- Where
- Tanzania
- Volunteers
- 22 people
- Sponsor
- Case Western Reserve University
Schizophrenia
A Study of Cariprazine in Patients With Chronic Stable Schizophrenia
This is an outpatient study to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.
- Trial name
- NCT00839852
- Testing
- Cariprazine
- Where
- 65 sites in United States, India and 3 more
- Volunteers
- 97 people
- Sponsor
- Forest Laboratories
Bipolar Disorder, Schizophrenia
Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders
Persons with serious mental illness (SMI) are at increased risk of cardiovascular disease (CVD). The goals of this study are to test a treatment, Life Goals Collaborative Care to help promote health behavior change and improve…
- Conditions
- Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder
- Trial name
- NCT01487668
- Testing
- Life Goals Collaborative Care
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- VA Office of Research and Development
Diabetes, Asthma
Integrated Care (IC) Models for Patient-Centered Outcomes
Multiple chronic conditions (MCC) are widely recognized as the U.S. public health challenge of the 21st century. These physical and behavioral health conditions take a large toll on those living with chronic diseases, including…
- Conditions
- Diabetes, Asthma, Chronic Obstructive Pulmonary Disease, Hypertension
- Trial name
- IC (NCT03451630)
- Testing
- High-Touch, High-Tech, Optimal Discharge Planning
- Where
- United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Schizophrenia, Chronic Illness
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
This project evaluates the implementation and effectiveness of a care model to improve treatment for schizophrenia within the context of diverse VA practices and priorities.
- Conditions
- Schizophrenia, Chronic Illness, Weight Gain, Psychotic Disorder
- Trial name
- EQUIP-2 (NCT00137280)
- Testing
- Collaborative Chronic Illness Care Model
- Where
- 8 sites in United States
- Volunteers
- 1,067 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
The primary objective of the study was to determine the safety of aripiprazole administered long-term in doses ranging from 10 to 30 mg per day as a maintenance therapy in subjects with chronic or first episode of schizophrenia.
- Trial name
- NCT02435836
- Testing
- Aripiprazole
- Volunteers
- 631 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Study of Efficacy of PEAR-004 in Schizophrenia
The purpose of the study was to determine in patients currently being administered antipsychotic pharmacotherapy whether PEAR-004 could further reduce symptoms of schizophrenia as measured by the Positive and Negative Syndrome…
- Trial name
- NCT03751280
- Testing
- PEAR-004
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus
This study is a six-week, open label trial of the novel antipsychotic agent, ziprasidone, added to a stable dose of clozapine or olanzapine in 40 diabetes mellitus patients, patients with an impaired fasting glucose or insulin…
- Trial name
- NCT00351000
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with chronic phase or elderly schizophrenia.
- Trial name
- NCT01625897
- Testing
- MP-214, Risperidone
- Where
- Japan
- Volunteers
- 125 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia
A Multicenter Study of NAP (AL-108) in Schizophrenia
The TURNS is a NIMH-funded contract for the evaluation of new compounds for the treatment of cognitive impairments in schizophrenia (HHSN 27820044 1003C; P.I.: Steve Marder, M.D.).
- Trial name
- AL-108 (NCT00505765)
- Testing
- AL-108
- Where
- 8 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of California, Los Angeles
Chronic Pain, Schizophrenia
Assessment and Treatment for Chronic Pain in Veterans With Serious Mental Illness
Chronic pain has a highly negative impact on Veterans, especially those with serious mental illness (SMI). Chronic pain leads to poorer mental health and physical functioning, and represents a critical obstacle to rehabilitation…
- Conditions
- Chronic Pain, Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- CPSMI (NCT04118283)
- Testing
- Cognitive Behavioral Therapy for Chronic Pain, Health and Wellness
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- VA Office of Research and Development
Chronic Schizophrenia
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term…
- Trial name
- PEARL 3 Ext (NCT00789698)
- Testing
- Lurasidone HC1, Quetiapine XR
- Where
- 65 sites in United States, Colombia and 4 more
- Volunteers
- 240 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Disease, Mental Disorder
Reducing Cardiovascular Risk in Adults With Serious Mental Illness
This purpose of this study is to adapt, implement and test the ability of a sophisticated point-of-care electronic health record-based clinical decision support that identifies and prioritizes all available evidence-based…
- Conditions
- Chronic Disease, Mental Disorder, Health Behavior, Bipolar Disorder
- Trial name
- SMIWizard (NCT02451670)
- Testing
- Prioritized Clinical Decision Support
- Where
- 3 sites in United States
- Volunteers
- 10,347 people
- Sponsor
- HealthPartners Institute
Chronic Schizophrenia
The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study
The purpose of this project is to examine brain function before, during, and after the administration of tDCS (Transcranial Direct Current Stimulation). The brain can perform its job well or poorly depending on many things.
- Trial name
- NCT02421146
- Testing
- Transcranial direct current stimulation
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Transcranial Direct Current Stimulation, Smoking, Cigarette
tDCS and Cognitive Training Intervention for Chronic Smokers With Schizophrenia
This study is being done to develop new methods to help smokers with schizophrenia to successfully reduce their smoking and/or quit. This is not a treatment study, but will help find new techniques to create better treatments.
- Conditions
- Transcranial Direct Current Stimulation, Smoking, Cigarette, Schizophrenia
- Trial name
- TACTICSS (NCT03588728)
- Testing
- Transcranial Direct Current Stimulation, Cognitive Remediation (CR)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pittsburgh